tipifarnib has been researched along with Ovarian Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kwon, M; Lee, DW; Lee, HN; Lee, W | 1 |
| Anderson, E; Bundred, NJ; Clarke, RB; Knox, F; Morris, J; Wärnberg, F; White, D | 1 |
2 other study(ies) available for tipifarnib and Ovarian Neoplasms
| Article | Year |
|---|---|
Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells.
Topics: Acetophenones; Benzopyrans; Cell Line, Tumor; Cell Survival; Female; Forkhead Box Protein M1; GTP Phosphohydrolases; Humans; Membrane Proteins; Ovarian Neoplasms; Pyridines; Quinazolines; Quinolones; Signal Transduction; Thiophenes | 2021 |
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.
Topics: Animals; Breast Neoplasms; Calcinosis; Carcinoma, Intraductal, Noninfiltrating; Cell Division; Cell Line, Tumor; Farnesyltranstransferase; Female; Humans; Mammography; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Quinolones; Transplantation, Heterologous | 2006 |